JEAN CHRISTOPHE 4

What Happened
Jean Christophe, a director of Rhythm Pharmaceuticals (RYTM), exercised or converted 4,712 derivative securities on June 23, 2026. The filing also shows a matching disposition of 4,712 shares at $0.00 the same day (reported as a derivative disposition). On June 24, 2026, he was granted two awards totaling 6,015 restricted stock units (3,691 RSUs and 2,324 RSUs) at $0.00. The filing reports no cash paid or received in these entries.

Key Details

• Transaction dates and reported prices: 6/23/2026 — exercise/conversion of 4,712 derivatives (acquired) and disposition of 4,712 shares at $0.00 (disposed); 6/24/2026 — awards of 3,691 RSUs and 2,324 RSUs at $0.00 (acquired).
• Total new RSUs granted: 6,015 RSUs (each RSU = contingent right to one share per footnote).
• Shares owned after transaction: Not disclosed in the provided excerpt.
• Footnotes of note: F1 — each RSU converts to one share; F2/F4 — RSU vesting/expiration details (some RSUs noted as fully vested or set to vest by the earlier of June 24, 2027 or the day before the 2027 annual meeting, subject to continued service); F3 — option vesting schedule referenced.
• Timeliness: Form 4 was filed on 2026-06-25 for transactions on 6/23–6/24, which is within the standard two-business-day reporting window (filed timely).

Context

• The paired exercise and $0.00 disposition often indicates that shares were surrendered to the issuer to cover exercise costs or tax withholding (a non-cash settlement), though the filing lists the disposition as a derivative and reports no cash proceeds.
• The RSU grants are awards (not purchases) and represent rights to receive shares subject to the vesting terms in the footnotes. Such awards do not necessarily indicate immediate market sentiment.
• No cash purchases or open-market sales are reported here; these are internal equity conversions and awards.